Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 29;16:821–839. doi: 10.2147/PPA.S346660

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 Varnado et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Medications used during 12-month baseline and 12-month follow-up period in matched (A) CGRP mAb and SOC and (B) galcanezumab and SOC cohorts.

Notes: ^a,bRefer to Tables 1 and 2 for medication details under each treatment category. Chi-square test was used to compare cohorts during baseline and during follow-up. Temporal comparisons were not conducted. *p < 0.05, **p < 0.01, ***p < 0.001.

Abbreviations: CGRP mAb, calcitonin gene-related peptide ligand or receptor-targeted monoclonal antibody; DHE, dihydroergotamine; IV, intravenous; NSAIDs, nonsteroidal anti-inflammatory drugs; SOC, standard-of-care.